Rao Deepa, Butt Zeeshan, Rosenbloom Sarah, Robinson Don, Von Roenn Jamie, Kuzel Timothy M, Cella David
Center on Outcomes, Research and Education, Evanston Northwestern Healthcare, Evanston, Illinois, USA.
J Pain Symptom Manage. 2009 Aug;38(2):291-8. doi: 10.1016/j.jpainsymman.2008.08.013. Epub 2009 Apr 8.
The development and validation of measures that provide disease-specific, patient-reported outcomes have become increasingly relevant in the care of cancer patients, especially for assessing symptoms from the patient's perspective. Recently, two patient symptom questionnaires were developed for kidney cancer patients, the Renal Cell Carcinoma-Symptom Index (RCC-SI) and the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI). This article describes the development of the revised FKSI scale (FKSI-19) and reconciles its use with the RCC-SI. Fifty participants with advanced kidney cancer commented on their symptoms and concerns about kidney cancer and this input was used to revise FKSI items. These patients also completed the RCC-SI, the Functional Assessment of Cancer Therapy-General (FACT-G), and an older version of the FKSI scale. We qualitatively reviewed item wording and content coverage across the two instruments, examined correlations between the scales, and calculated basic psychometrics on each scale. We found that the FKSI-19 and the RCC-SI addressed similar symptoms. Qualitative and descriptive statistical analyses demonstrated considerable overlap between the two instruments (rho=0.88, P<0.001). Cronbach's alpha for the FKSI-19 and RCC-SI were both good, at 0.86 and 0.92, respectively. The FKSI-19 has some advantages over the RCC-SI. The FKSI-19 has more clarity in item phrasing, is shorter in length, and covers a similar breadth of disease-based symptoms when compared to the RCC-SI.
开发并验证能够提供特定疾病、患者报告结局的测量工具，在癌症患者护理中变得越来越重要，尤其是从患者角度评估症状时。最近，为肾癌患者开发了两份患者症状问卷，即肾细胞癌症状指数（RCC-SI）和癌症治疗功能评估-肾脏症状指数（FKSI）。本文描述了修订后的FKSI量表（FKSI-19）的开发过程，并协调了其与RCC-SI的使用。五十名晚期肾癌患者对他们的症状以及对肾癌的担忧发表了意见，这些意见被用于修订FKSI条目。这些患者还完成了RCC-SI、癌症治疗功能评估-通用量表（FACT-G）以及旧版的FKSI量表。我们定性审查了这两种工具的条目措辞和内容覆盖范围，检查了量表之间的相关性，并计算了每个量表的基本心理测量指标。我们发现FKSI-19和RCC-SI涉及相似的症状。定性和描述性统计分析表明这两种工具之间存在相当大的重叠（rho=0.88，P<0.001）。FKSI-19和RCC-SI的Cronbach's alpha系数都很好，分别为0.86和0.92。FKSI-19相对于RCC-SI有一些优势。与RCC-SI相比，FKSI-19的条目措辞更清晰，长度更短，并且涵盖了类似广度的基于疾病的症状。
